ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1319

The Association of Rheumatoid Arthritis in Patients with Vitiligo: Systematic Review and Meta-Analysis

Nattanicha Chaisrimaneepan1, thunyaporn Khoruamklang2, Pitchaporn Yingchoncharoen3, Tulaton Sodsri4 and Miriam Paz3, 1Texas Tech University Health Sciences Center, Lubbock, TX, 22Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, bangkok, Thailand, 3Texas Tech University Health Sciences Center, Lubbock, 4Department of Medicine, Texas Tech University Health Sciences Center, Bangkok, Thailand

Meeting: ACR Convergence 2025

Keywords: rheumatoid arthritis, Tissue Engineering

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (1306–1346) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Vitiligo is associated with many autoimmune diseases, but its association with rheumatic disease has not been well-defined. Therefore, we conducted a systematic review and meta-analysis to study the association of vitiligo and occurrence of rheumatoid arthritis.

Methods: A comprehensive literature review was conducted by searching for publishedarticles indexed in Pubmed, Embase, Google Scholar, and MEDLINE databases from inception throughJanuary 2025. Identify all observational studies that compared the incidence or risk of developing rheumatoid arthritis (RA) in vitiligo patients compared to non-vitiligo. Pooled risk ratio (RR) and 95% confidence interval (CI) were calculated using a random-effect model, DerSimonian and Laird. Publication bias was analyzed with the Egger test.

Results: A total of 262 articles were identified. Following PRISMA for study selection, 6 studies fulfilled the inclusion criteria and were included in the meta-analysis. The risk of developing rheumatoid arthritis among vitiligo patients was significantly higher than in non-vitiligo patients with the pooled RR of 1.47, 95% CI 1.13-1.91: I2 92.42%. Publication bias analyzed by the Egger test showed no small-study effects with p value of 0.83.

Conclusion: This analysis found that vitiligo is associated with a higher risk of developing rheumatoid arthritis. Further investigation is required to determine the causal relationship.

Supporting image 1Forest plot of the meta-analysis of rheumatoid arthritis in patients with vitiligo


Disclosures: N. Chaisrimaneepan: None; t. Khoruamklang: None; P. Yingchoncharoen: None; T. Sodsri: None; M. Paz: None.

To cite this abstract in AMA style:

Chaisrimaneepan N, Khoruamklang t, Yingchoncharoen P, Sodsri T, Paz M. The Association of Rheumatoid Arthritis in Patients with Vitiligo: Systematic Review and Meta-Analysis [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/the-association-of-rheumatoid-arthritis-in-patients-with-vitiligo-systematic-review-and-meta-analysis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-association-of-rheumatoid-arthritis-in-patients-with-vitiligo-systematic-review-and-meta-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology